CorMedix disclosed that its Phase III ReSPECT trial met its primary endpoint, showing non‑inferiority in fungal‑free survival at Day 90. Rezafungin achieved 60.7 % fungal‑free survival versus 59.0 % for the standard antimicrobial regimen, and the safety profile was favorable with fewer toxicity‑related discontinuations and drug‑drug interactions.
The company estimates that the U.S. market for REZZAYO in the prophylaxis indication exceeds $2 billion. A pre‑NDA meeting with the FDA is planned, followed by a supplemental NDA submission in the second half of 2026. Rezafungin enjoys orphan drug exclusivity through 2035 and patent protection through 2038, providing a strong commercial moat for the expanded indication.
These results position CorMedix to broaden REZZAYO’s indication beyond treatment of candidemia and invasive candidiasis, potentially unlocking a sizable new revenue stream. The achievement dovetails with the company’s recent acquisition of Melinta Therapeutics, which expanded its anti‑infective portfolio and sales base. Strong performance of the company’s commercial product DefenCath and the strategic focus on high‑margin anti‑infective therapies reinforce the long‑term value proposition of the expanded REZZAYO program.
Joseph Todisco, Chairman & Chief Executive Officer of CorMedix Therapeutics, said, "We believe this positive outcome of the Phase III ReSPECT study meaningfully strengthens REZZAYO's long‑term value proposition to patients and clinicians."
Investors responded positively to the announcement, reflecting confidence in the expanded market opportunity, the robust safety profile, and the clear regulatory pathway. Analysts highlighted the $2 billion+ market potential and the extended exclusivity as key drivers of the favorable reception.
The positive topline results reinforce CorMedix’s strategy to grow its anti‑infective pipeline and capitalize on the company’s recent strategic acquisitions. The data provide a strong foundation for future commercialization and underscore the company’s ability to deliver clinically meaningful outcomes in high‑need patient populations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.